Fellowships in Urologic Oncology
The Urologic Oncology Branch offers a two- to three-year fellowship program in clinical service and laboratory training for urologic surgeons. Clinical training during first year includes rotation to urological surgery service; provides consult service to patients, care for inpatients/outpatients on clinical protocols, and performs surgery. From 12-24 months, time is devoted to basic or clinical science research in laboratories/clinical programs, and one can choose to concentrate in either field. Fellows have their own patients which they follow to develop an understanding of care continuity and multidisciplinary management of patients with urologic cancers. Core curriculum covers prostate, bladder, kidney, testis and penile cancer plus experience with advanced minimally invasive surgical techniques and management of patients with locally advanced and advanced genitourinary malignancies and systemic therapy. The “bench-to-bedside” proximity in the new Mark O. Hatfield Clinical Research Center provides a crucial link in rapidly moving biomedical findings in the laboratory into the mainstream of clinical practice. The Clinical Center combines research laboratories with a 250 bed hospital. There are currently over 1,500 active clinical research protocols at the Clinical Center and over 50,000 inpatient days and nearly 100,000 outpatient visits per year. Our Urologic Oncology Fellows rotate on the Urology Service at George Washington University.
Research in molecular genetic basis of urologic malignancies and work on development of new forms of diagnosis/therapy for patients with these cancers is done in collaboration with other branches/labs at the NCI and is continually evolving. Solid grounding in cancer genetics and molecular biology and unique interface between basic and clinical research; also includes participation in lab/seminars/ journal clubs, NIH-wide lectures, seminars, and on-campus, short-term molecular biology and clinical research training courses, weekly clinical urology conferences and clinical trials of new forms of therapy for patients with localized as well as advanced forms of urologic cancers.
The Urologic Oncology Branch Urologic Oncology Fellowship Program is accredited by the Society of Urologic Oncology (SUO), and commences July 1. Applications are accepted throughout the year. Individuals interested in applying should send a cover letter expressing their intention to be considered for this fellowship, and include their SUO Common Application, a Curriculum Vitae and three letters of recommendation to:Peter A. Pinto, M.D., Director Urology Oncology Fellow Program Center for Cancer Research, National Cancer Institute, Bldg. 10 CRC, Rm 2W-5940, Bethesda MD 20892 firstname.lastname@example.org
Candidates accepted to the fellowship program will be appointed as a Clinical Fellow in the Civil Service. The stipend is based upon training, experience, etc. Benefits include accruable annual and sick leave, moving and travel expenses to place of duty; health and life insurance policies are available. Once accepted, fellows will be provided with information detailing the benefits of the Civil Service appointment. NIH Loan Repayment Program; NCI/AFUD Fellows are also eligible to apply for the NIH Loan Repayment program.
The NCI Urologic Oncology Fellowship is open to urologists who have completed a urologic surgery residency or residents who have completed at least one year of surgical training. Three positions per year are available for this two-year fellowship program, with a potential option for a third year of laboratory work. Applications are accepted throughout the year and decisions are made as qualified applicants are identified.
Fellows participate in two clinical review and teaching sessions each week; daily rounds, x-ray conferences and search and pathology seminars round out the teaching program. Training courses, seminars and journal clubs, lectures and seminars are part of the initial year. Fellows rotate on the urologic surgery services and provide consult service to all patients at the NIH Clinical Center.